Partner Clare O’Brien (New York-Mergers & Acquisitions) joined a panel of other M&A experts to discuss whether deal fatigue exists now, and what larger trend changes they foresee for large-cap pharma, small to mid-size biotechs, and investors.

View a summary of the panel discussion.